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To	improve	the	technology	of	cancer	biotherapy,	it	is	
important	to	understand	functions	and	mechanism	of	ac-
tion	of	cytokines	that	are	involved	in	attraction	of	immuno-
competent	cells	to	immune	reactions	and	elevate	ability	
of	T-lymphocytes	to	eliminate	malignant	cells.	That’s	why	
biological	modifiers	of	immune	response	are	often	used	
in	technology	of	preparation	of	cancer	vaccines	(CV)	or	
are	used	as	their	components.	In	the	most	simple	variant,	
cytokines	are	administered	together	with	antigen	and	
stimulate	immune	response	against	it	[1–4].	
Interferon	(IFN)	is	one	of	the	key	modulators	of	im-
mune	response	influencing		the	processes	of	antigen	
recognition,	differentiation,	and	functional	activity	of	
immunocompetent	cells.	The	most	interesting	aspects	
of	 studies	are	effects	of	 IFN	 related	 to	elevation	of	
tumor	 immunogenecity	and	 its	altered	sensitivity	 to	
cytotoxic	action	of	T-lymphocytes	[5].	
The	role	of	IFN	in	combination	with	other	biological	
agents	or	chemopreparations	became	a	subject	of	
intense	studies.	The	research	of	effects	of	IFN	upon	
combined	use	with	active	specific	immunization	is	of	
special	interest	[1,	6,	7].	IFNs,	including	IFN-α2,	-β,	-γ,	
are	potent	inducers	of	expression	of	genes	of	major	
histocompatibility	complex.	Exactly	this	property,	apart	
from	indirect	immunomodulating	action	is	one	of	the	
main	reasons	for	use	of	IFN	in	immunotherapy	[8].	The	
facts	on	high	anticancer	acitivity	of	IFN	in	the	case	of	
metastatic	melanoma	and	the	increasing	number	of	
reports	about	positive	 influence	of	 this	cytokine	on	
elongation	of	relapse-free	period	in	the	patients	after	
tumor	 resection	are	evidencing	 the	expediency	of	
combined	use	of	IFN	with	CV	[6,	9,	10].	The	mecha-
nisms	of	synergistic	action	of	vaccine	and	IFN	possibly	
will	differ	dependent	on	composition	of	 the	vaccine	
and	 the	 immune	 reactions	 that	provide	an	effect	of	
immunization.	In	numerous	reports	it	has	been	shown	
that	IFN-α	possesses	the	highest	anticancer	action	[5,	
6,	8].	The	results	of	experimental	and	clinical	studies	
are	providing	the	grounds	for	the	use	of	IFN-α	as	an	
element	of	optimization	of	combined	therapy	directed	
on	the	decrease	of	metastasis	risk	and	improvement	
of	quality	of	life	of	oncological	patients	[10,	11].	
The	aim	of	present	 research	was	 to	evaluate	 the	
possibilities	of	the	use	of	immunomodulating	properties	
of	 IFN	for	elevation	of	the	efficacy	of	cancer	vaccine	
prepared	from	autologous	tumor	cells	with	the	use	of	
cytotoxic	lectin	(CL)	from	B. subtilis B-7025	[12,	13].
MATERIALS AND METHODS
The	experiments	were	carried	out	on	male	С57Вl	
2.5	months	old	mice	bred	in	the	vivarium	of	R.E.	Ka-
vetsky	Institute	of	Experimental	Pathology,	Oncology	
and	Radiobiology	NAS	of	Ukraine	(Kyiv,	Ukraine)	with	
the	use	of	experimental	model	of	Lewis	 lung	carci-
noma	 (LLC).	 Tumor	cells	were	 transplanted	 in	 the	
thigh	muscle	(by	5.0	х	105	vital	LLC	cells	per	animal).	
The	animals	were	treated	by	therapeutic	scheme	as	
follow:	1st	group	received	CV,	2nd	–	preparation	of	mu-
rine	IFN,	3rd	—	CV	+	IFN	by	combined	scheme.	In	this	
series	of	experiments,	the	group	of	untreated	animals	
(4th	group,	transplantation	control)	and	intact	animals	
(5th	group)	served	as	the	controls.	All	experiments	with	
animals	were	approved	by	local	ethic	committee.
CV	was	 prepared	 from	 grounded	 LLC	 tissue	
samples	 treated	with	cytotoxic	 lectins	of	В. subtilis 
B-7025	 (1	g	of	 tumor	 tissue	per	10	ml	CL	solution	
(0.5	mg/ml))	and	stored	at	–18	 ˚С	[12].	Preparation	
of	CL	was	isolated	from	culture	medium	of	В. subtilis 
B-7025 by	the	method	described	earlier	[14].	CV	was	
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injected	subcutaneously	(s.	c.)	by	0.3	ml	at	the	days	
1,	4,	8,	11,	15	after	LLC	transplantation.	
Preparation	of	IFN-alpha	was	prepared	according	
to	[15].	IFN	solution	was	prepared	ex tempore	and	ad-
ministered	5	times	intraperitoneally	(i.p.)	by	1000	units	
in	0.5	ml	of	physiologic	solution	24	h	prior	to	CV	ad-
ministration.	Such	scheme	for	IFN	administration	was	
chosen	of	the	base	of	results	of	studies	on	combined	
use	of	CV	with	other	immunomodulating	preparations	
[16,	17].	Efficacy	of	treatment	was	evaluated	by	tumor	
growth	inhibition	index	and	average	life	span	(ALS)	of	
experimental	animals.	
Immunologic	research	included	determination	of	
cytotoxic	activity	of	T-lymphocytes	(CTL)	and	natural	
killer	 (NK)	cells	 in	cytotoxic	 tests	 in vitro	 [18],	cyto-
chemical	 activity	of	peritoneal	macrophages	 (MP)	
using	test	with	nitroazole	blue	(NBT)	[19],	the	level	
of	 production	 of	 tumor	 necrosis	 factor	 (TNF)	 by	
MP	 in vitro	using	TNF-sensitive	L-929	cells	[20],	the	
levels	of	production	of	 IL-1	by	adherent	 fraction	of	
spleen	lymphocytes,	and	IL-2	—	by	nonadherent	one	
using	standard	radiometric	methods	[21,	22].	These	
studies	were	carried	out	at	the	days	28	and	45	after	
tumor	cells	transplantation.
Statistical	analysis	was	carried	out	using	Student’s	
t-criterium;	the	values	p	<	0.05	were	considered	sig-
nificant	[23].
RESULTS AND DISCUSSION
The	study	of	LLC	growth	evidenced	on	significant	
increase	of	the	duration	of	latent	period	and	pronounced	
inhibition	of	tumor	growth	upon	combined	use	of	CV	and	
murine	IFN	compared	with	these	indexes	in	the	groups	of	
transplantation	control	or	upon	separate	use	of	CV	and	IFN	
(Fig.	1).	Analogous	peculiarities	have	been	registered	dur-
ing	analysis	of	ALS	of	experimental	animals	(Table	1).	In	the	
group	of	LLC-bearing	mice	that	received	CV	at	monoregi-
men	(group	1),	 insignificant	 increase	of	the	duration	of	
latent	period	has	been	observed	as	well	as	tumor	growth	
inhibition	by	24–45%,	that	lead	to	significant	increase	of	
ALS.	Administration	of	CV	with	IFN	(group	3)	led	to	signifi-
cant	increase	of	its	efficacy:	the	duration	of	latent	period	
elevated	by	25%,	whilst	tumor	growth	inhibition	increased	
by	35–40%.	ALS	indexes	in	groups	1	and	3	were	53.71	±	
4.0	and	65.0	±	2.9	days	respectively	(p	<	0.05).	It	should	
be	stressed	that	upon	separate	use	murine	IFN	also	was	
effective	compared	to	control	 indexes:	the	duration	of	
latent	period	elevated	by	39%,	ALS	—	by	38%	(54.8	±	
3.75	and	39.8	±	1.8	days	respectively,	p	<	0.05).	So,	the	
obtained	results	have	shown	that	aadministration	of	IFN	
to	LLC-bearing	mice	at	monoregimen	or	in	combination	
with	vaccine	elevates	vaccine’s	efficacy.	
The	study	of	immunologic	indexes	allowed	to	anali-
ze	their	changes	in	treated	animals	(Table	2).	In	control	
group	of	LLC-bearing	mice	at	the	day	28	the	cytotoxic	
activity	of	NK	cells	and	CTL	has	been	restored	at	relatively	
high	level	(labeling	index	(LI)	was	+322.6%	and	+196.0%,	
respectively	compared	to	intact	control).	These	indexes	
as	well	as	MP	activity	(LI	=	+79.4%)	were	significantly	
higher	than	these	of	intact	animals	(p	<	0.05).
Fig. 1. Duration	of	latent	period	(a)	and	tumor	growth	inhibition	
of	experimental	animals	
*p < 0.05	compared	to	control	of	transplantation.
Table 1. Average life span (ALS) and duration of latent period in mice 
bearing Lewis lung carcinoma 
Group Treat-ment
Number 
of ani-
mals
ALS, days Latent period, days
Х ± m t LI, % Х ± m t LI, %
I CV 14 53.7 ± 4.0 2.8* 35.0 11.1 ± 1.3 1.4 13.5
ІІ IFN 15 54.8 ± 3.8 3.1* 37.7 12.5 ± 1.1 2.5* 28.3
ІІI CV + IFN 11 65.0 ± 3.9 5.8* 63.3 13.5 ± 1.6 2.7* 38.2
ІV Control 10 39.8 ± 1.8 – – 9.0 ± 0.8 – –
*p < 0.05	compared	to	control	of	transplantation.
Table 2. Activity of effectors of cellular antitumor immunity in mice 
bearing Lewis lung carcinoma (day 28 of tumor growth)
Group Treatment CI, % Activity of MP in NBT-testNK CTL
I CV 43.2 ± 2.3*, ** 7.8 ± 4.5*** 0.176***
ІІ IFN 9.4 ± 4.7*** 28.0 ± 4.3* 0.243
IІІ CV + IFN 10.6 ± 5.2*** 34.6 ± 2.4* 0.600*, ***
ІV Control of transplantation 35.5 ± 2.6* 24.5 ± 13.8* 0.393*
V Intact control 6.4 ± 2.0 2.0 ± 1.2 0.219
*р < 0.05 compared to intact control;
**0.05 < р < 0.1 compared to control of transplantation;
***р < 0.05 compared to control of transplantation.
Administration	of	CV	to	mice	resulted	in	the	marked	
NK	cells	activation	(43.2	±	2.3	versus	35.5	±	2.6%	for	
group	of	transplantation	control,	p	<	0.05);	at	the	same	
time	the	indexes	of	activities	of	CTL	and	MP	remained	
at	 the	 level	of	 intact	control	 and	were	significantly	
lower	 than	 these	of	 transplantation	control	group.	
Upon	the	use	of	IFN,	the	situation	was	different	—	the	
preparation	acted	mainly	via	activation	of	CTL.	Com-
bined	treatment	with	both	agents	(CV	+	IFN)	along	by	
increased	specific	 response	was	accompanied	with	
elevation	of	MP	activity	(compared	to	transplantation	
control	group,	LI	was	+41%	and	+52,7%,	respectively,	
p	<	0.05),	whilst	NK	cells	cytotoxicity	remained	at	the	
level	of	that	of	intact	animals.	
It	is	known	that	along	with	effectors	of	specific	and	
natural	resistance,	cytokines	(IL-1,	IL-2,	TNF,	IFN)	play	
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an	important	role	in	anticancer	defense	of	the	body.	
As	biologic	modifiers	of	 immune	response,	 they	are	
often	used	in	technology	of	preparation	of	cancer	vac-
cines	or	are	used	as	their	components.	That’s	why	one	
may	suppose	that	positive	effects	of	vaccine	therapy	
combined	with	 IFN	could	be	 in	part	explained	by	 its	
influence	on	the	level	of	production	at	least	some	of	
mentioned	cytokines,	in	particular,	TNF,	IL-1,	IL-2.
At	the	day	28	of	tumor	growth,	production	of	TNF	
in	animals	from	transplantation	control	group	was	de-
creased	compared	with	intact	control:	this	is	evidenced	
by	relatively	 low	 titer	of	TNF	(LI	=	–51.9%,	р	<	0.05)	
(Table	3).	It	should	be	noted	that	at	this	time	point	in	
experimental	groups	(groups	І–ІІІ)	production	of	TNF	
remained	at	 the	 level	of	 intact	animals	only	 in	mice	
that	received	IFN	(the	titer	of	TNF	activity	in	this	group	
was	2.55	±	0.25	log2	and	was	twice	higher	than	such	
indexes	of	transplantation	control	group	as	well	as	other	
experimental	groups.	At	this	period	no	alterations	in	IL-1	
activity	have	been	observed	in	all	studied	groups.
Level	of	IL-2	production	in	the	supernatants	of	cul-
tured	lymphocytes	isolated	at	day	28	from	the	animals	
of	transplantation	control	group	was	significantly	lower	
than	that	of	intact	animals	(LI	=	–56.8%,	р	<	0.05).	At	
this	period	in	mice	from	groups	І and ІІ the titer of IL-2	 	 	 	 	 	 	
activity	was	practically	equal	to	that	of	tumor-bearing	
control	mice	 (LI	was	–35%	and	–16%,	 respectively,	
compared	to	transplantation	control	group).	The	titers	
of	IL-2	activity	in	mice	that	received	IFN	+	CV	were	close	
to	these	of	intact	control	(LI	=	–36%	compared	to	in-
tact	control,	and	+46.8%	compared	to	transplantation	
control	group)	(Table	4).	It’s	interesting	that	exactly	in	
this	group	the	highest	percent	of	animals	(25%)	that	
didn’t	develop	tumors	has	been	registered.	
Table 4. Production of IL-2* by Т-lymphocytes from spleen of С57Bl mice 
after transplantation of Lewis lung carcinoma cells 
Group of animals Activity of CTL, CI, %
Terms of observation (days after 
tumor cell transplantation) 
28 45
CV 7.8 ± 4.52 < 1 log2
1, 2 –
CV + IFN 34.6 ± 2.41 2.26 ± 0.011, 2 2.68 ± 0.071, 3
IFN 28.0 ± 4.31 1.29 ± 0.011, 2 –
Control of transplantation 24.5 ± 3.81 1.54 ± 0.11 –
Intact control 2.0 ± 1.2 3.57 ± 0.08
*Production of IL-2 is expressed in titres of activity, log2;
1p < 0.05 compared to intact control; 2p < 0.05 compared to control of 
transplantation; 3p < 0.05 compared to previous observation point.
That’s	why	it	looks	reasonable	to	analyze	the	state	
of	 effectors	of	 anticancer	defense	 (CTL,	NK,	MP)	
(Fig.	2)	 in	 these	animals.	 Immunologic	 research	has	
been	carried	out	at	day	45	after	LLC	transplantation	(at	
this	term	all	animals	from	transplantation	control	group	
died,	ALS	=	39.8	±	1.8	days).	The	results	have	shown	
significant	activation	of	effector	cells	of	specific	and	
unspecific	defense	(p	<	0.05).	At	this	term	of	observa-
tion	the	highest	CTL	activity	has	been	registered	in	mice	
that	received	IFN	separately	or	in	combination	with	CV	
(LI	was	+993.0%	and	+615.6%	respectively,	p	<	0.05,	
compared	to	intact	animals).	The	indexes	of	NK	and	MP	
activity	in	mice	of	experimental	groups	were	similar	and	
were	significantly	higher	than	control	ones.	
Fig. 2. Activity	of	effectors	of	cell	immunity	in	mice	with	unde-
veloped	tumors	(day	45	after	LLC	transplantation),	that	received	
CV	+	IFN	by	combined	scheme:	a	—	cytotoxicity	of	NK	and	CTL,	
b	—	activity	of	MP	in	NBT-test.
In	conclusion,	the	presented	data	allow	suppose	
that	the	use	of	IFN	at	monoregimen	or	in	combination	
with	CV	favors	restoraton	of	the	functional	reserve	of	
all	effectors	of	antitumor	defense	of	 the	body,	and	
that	combined	administration	of	CV	and	IFN	could	be	
considered	as	a	promising	 tool.	Further	exploration	
of	synergistic	action	of	 these	preparations	could	be	
useful	 for	 the	development	of	effective	schemes	of	
biotherapy	of	oncologic	diseases.
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ЭКСПЕРИМЕНТАЛЬНОЕ ИССЛЕДОВАНИЕ ЭФФЕКТИВНОСТИ 
КОМБИНИРОВАННОГО ИСПОЛЬЗОВАНИЯ 
ПРОТИВООПУХОЛЕВОЙ ВАКЦИНЫ И ИНТЕРФЕРОНА
Цель: исследовать в эксперименте эффективность комбинированной схемы введения противоопухолевой вакцины (ПВ) 
и интерферона (ИФН). Материалы и методы: карциному легкого Льюис (КЛЛ) трансплантировали мышам-самцам C57Bl. 
Для лечения использовали ПВ, приготовленную из клеток КЛЛ с помощью цитотоксических лектинов B. subtilis B-7025, 
и препарат мышиного ИФН. Терапевтический эффект оценивали путем измерения объема солидной опухоли и анализа средней 
продолжительности жизни опытных животных. Иммунологическое исследование включало определение противоопухолевой 
цитотоксичности Т-лимфоцитов (ЦТЛ) и природных киллерных клеток (ПКК) радиометрическим методом; функциональной 
активности перитонеальных макрофагов (Мф) в колориметрическом НСТ-тесте; определение титров фактора некроза 
опухоли (ФНО), интерлейкинов-1 и -2. Результаты: показано, что использование препарата ИФН существенно повышает 
эффективность вакцинотерапии солидной формы модельной КЛЛ: на 25% повышается продолжительность латентного 
периода, на 28% — средняя продолжительность жизни мышей, на 35–40% — индекс торможения опухолевого роста. При 
комбинированном применении ПВ и ИФН отмечают существенную активацию клеток-эффекторов как неспецифической 
(Мф), так и специфической (ЦТЛ) иммунной защиты. Выводы: полученные результаты свидетельствуют о перспективности 
разработки комбинированных схем введения ПВ с ИФН, позволяющих повысить эффективность вакцинотерапии.
Ключевые слова: противоопухолевая вакцина, интерферон, карцинома легкого Льюис, иммунные показатели.
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